IGF Oncology is developing novel cancer drugs that have better efficacy and lower side effects than existing cancer chemotherapy drugs.
Our lead drug, IGF-MTX is a conjugate of the effective chemotherapy drug methotrexate to a targeting protein. IGF-MTX was 15-times more effective than methotrexate in animal studies, and with much lower side effects. It has completed a Phase 1 study in advanced solid tumors and was effective even as a single agent in persons with heavily pre-treated advanced tumors that had progressed on approved drugs. And it had extremely low side effects, with no decrease in blood cell counts, unlike methotrexate and all chemotherapy drugs.
IGF-MTX is now in a second clinical trial at the Mayo Clinic in the blood cancer myelodysplastic syndrome (MDS). Early results again show very promising efficacy
and low side effects. https://clinicaltrials.gov/ct2/show/NCT03175978
We also have a further pipeline of targeted cancer drugs.
IGF Oncology, LLC, is a Minnesota company registered in Delaware.